RPL-554|LS-193855;RPL 554;RPL554

Cas No.:	298680-25-8
Chemical Name:	9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one
Synonyms:	LS-193855;RPL 554;RPL554
SMILES:	C12=C/C(=N\C3=C(C)C=C(C)C=C3C)/N(CCNC(=O)N)C(=O)N1CCC1=C2C=C(OC)C(OC)=C1
Formula:	C₂₆H₃₁N₅O₄
M.Wt:	477.554
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

RPL-554 (LS-193855, RPL554) is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively; inhibits LPS-induced TNFα release from human monocytes with IC50 of 0.52 uM, and proliferation of human mononuclear cells to phytohemagglutinin (IC50=0.46 uM); significantly inhibits eosinophil recruitment following antigen challenge in ovalbumin-sensitized guinea pigs (10mg/kg).

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC11671	RPL-554	RPL-554 (LS-193855, RPL554) is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively.
DC9583	Oglemilast	Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.
DC9584	(R)-(-)-Rolipram	(R)-(-)-Rolipram is a potent and cAMP-specific PDE4 inhibitor with IC50 of 0.22 uM; 2.5-fold more potent than (+)-rolipram (IC50= 2.58 uM) in inhibiting membrane-bound PDE 4.